ACCESS Newswire·Jul 6, 2026, 9:00 AM ET

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

MIRA Pharmaceuticals announced positive preclinical data for SKNY-1, an oral candidate for obesity & addiction disorders.
The optimized oral formulation demonstrated favorable bioavailability, reproducible systemic exposure, robust brain penetration, & substantial liver exposure.
Peak plasma concentrations occurred 6 to 12 hours post-dose, supporting potential once-daily oral dosing.
Tissue distribution was consistent across multiple animals, indicating reliable delivery to target organs.
SKNY-1 combines biased CB1 modulation, partial CB2 agonism, & selective MAO-B inhibition to differentiate from earlier CB1 therapies like rimonabant.
The compound showed robust brain penetration without anxiety-related behaviors in preclinical behavioral models.
Previous efficacy studies noted significant weight loss, preserved lean body mass, improved lipid parameters, & reduced compulsive feeding & nicotine-seeking.
MIRA plans to continue evaluating tissue exposure, pharmacodynamic activity, & therapeutic efficacy during further preclinical development.
SKNY-1 remains an investigational drug candidate with no FDA approval or established safety & efficacy in humans.